Europeans to Decide Whether to Further Restrict Diet Drug Acomplia This Week

Will diet drug Acomplia (rimonabant), taken this past year by more than 100,000 Europeans seeking to lose weight, be pulled from the European market out of concern over depressive and suicidal side-effects?

That decision will be...

Rimonabant may prevent and treat obesity-related liver disease

A new study on the effect of the anti-obesity drug rimonabant on liver function in obese rats found that it reduced markers of liver damage, decreased levels of pro-inflammatory proteins, and improved lipid profiles.

The results...

Sanofi: Diet Drug Acomplia Requires Indefinite Use to Keep Weight Off

Diet drug Acomplia (rimonabant) users might want to pay close attention to an issue that developer Sanofi-Aventis is now facing the need to address more openly with regulators (if not dieters): If you want to keep off the weight...

Sanofi pulls diet drug application from FDA

Sanofi withdraws Acomplia application from FDA following rejection from experts over reports of suicidal thoughts.

New European Recommendations on Diet Drug Acomplia May Be Published June 29th

A European regulatory review of diet drug Acomplia (rimonabant) may result in publication of new safety recommendations as early as June 29th, accordilng to a spokesperson for the European Medicines Agency (EMEA).

The EMEA said...